Xanthoceraside attenuates tau hyperphosphorylation and cognitive deficits in intracerebroventricular-streptozotocin injected rats

No abstract is available for this paper.

• Publication year

  2013

• Venue

  Psychopharmacology

• Publication date

  Unknown publication date

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1007/s00213-013-3240-4PMID 23958944
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Okadaic acid-induced Tau phosphorylation in rat brain: role of NMDA receptor.

  2013cited by this paper
• Lithium attenuates bupivacaine-induced neurotoxicity in vitro through phosphatidylinositol-3-kinase/threonine-serine protein kinase B- and extracellular signal-regulated kinase-dependent mechanisms.

  2012cited by this paper
• Pretreatment with memantine prevents Alzheimer-like alterations induced by intrahippocampal okadaic acid administration in rats.

  2012cited by this paper
• Greater cognitive deterioration in women than men with Alzheimer's disease: A meta analysis

  2012cited by this paper
• Central insulin resistance and synaptic dysfunction in intracerebroventricular-streptozotocin injected rodents.

  2012cited by this paper
• Over activation of hippocampal serine/threonine protein phosphatases PP1 and PP2A is involved in lead-induced deficits in learning and memory in young rats.

  2012cited by this paper
• Tau phosphorylation in human brain: relationship to behavioral disturbance in dementia.

  2012cited by this paper
• Α-mangostin, a polyphenolic xanthone derivative from mangosteen, attenuates β-amyloid oligomers-induced neurotoxicity by inhibiting amyloid aggregation.

  2012cited by this paper
• Functional significance of glycogen synthase kinase-3 regulation by serotonin.

  2012cited by this paper
• Gender differences in apolipoprotein D expression during aging and in Alzheimer disease.

  2012cited by this paper
• Implication of phosphatidylinositol-3 kinase/Akt/glycogen synthase kinase-3β pathway in ginsenoside Rb1's attenuation of beta-amyloid-induced neurotoxicity and tau phosphorylation.

  2011influential reference
• The Expression and Regulation of GSK-3â, CDK-5 and PP2A in Differentiated Neural Stem Cells of Rats

  2011cited by this paper
• In-vivo histamine H3 receptor antagonism activates cellular signaling suggestive of symptomatic and disease modifying efficacy in Alzheimer's disease.

  2011cited by this paper
• Post-translational modifications of tau protein: implications for Alzheimer's disease.

  2011influential reference
• Insulin receptor signaling in rat hippocampus: a study in STZ (ICV) induced memory deficit model.

  2011influential reference
• Nuclear protein phosphatase-1: an epigenetic regulator of fear memory and amygdala long-term potentiation.

  2011cited by this paper
• Hippocampal tauopathy in tau transgenic mice coincides with impaired hippocampus-dependent learning and memory, and attenuated late-phase long-term depression of synaptic transmission.

  2011cited by this paper
• Tau phosphorylation and neuronal apoptosis induced by the blockade of PP2A preferentially involve GSK3β.

  2011influential reference
• Inhibiting NF-κB activation and ROS production are involved in the mechanism of silibinin's protection against D-galactose-induced senescence.

  2011influential reference
• Effect of glycogen synthase kinase 3 β-mediated presenilin 1 phosphorylation on amyloid β production is negatively regulated by insulin receptor cleavage.

  2011cited by this paper
• Xanthoceraside attenuates amyloid β peptide25–35-induced learning and memory impairments in mice

  2011cited by this paper
• [Abeta(25-35) and ginsenoside Rb1 influence on the expression of GSK-3beta, CDK-5 and PP2A in differentiated neural stem cells of rats].

  2010cited by this paper
• Pregnenolone sulfate infused in lateral septum of male rats impairs novel object recognition memory

  2010cited by this paper
• Transgenic miR132 Alters Neuronal Spine Density and Impairs Novel Object Recognition Memory

  2010cited by this paper
• Spatial Learning and Expression Patterns of PP1 mRNA in Mouse Hippocampus

  2010cited by this paper
• Tau protein and tau aggregation inhibitors.

  2010cited by this paper
• UCLEAR PROTEIN PHOSPHATASE-1 : AN EPIGENETIC REGULATOR F FEAR MEMORY AND AMYGDALA LONG-TERM POTENTIATION

  2010cited by this paper
• Brain Switches Utilitarian Behavior: Does Gender Make the Difference?

  2010cited by this paper
• Icariin attenuates β-amyloid-induced neurotoxicity by inhibition of tau protein hyperphosphorylation in PC12 cells.

  2010cited by this paper
• HE N-TERMINAL 5-MER PEPTIDE ANALOGUE P 165 OF AMYLOID RECURSOR PROTEIN EXERTS PROTECTIVE EFFECTS ON SH-SY 5 Y ELLS AND RAT HIPPOCAMPUS NEURONAL SYNAPSES

  2010influential reference
• Diabetes synergistically exacerbates poststroke dementia and tau abnormality in brain.

  2010influential reference
• Positive modulation of alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptors reverses sub-chronic PCP-induced deficits in the novel object recognition task in rats.

  2010cited by this paper
• Tau-directed drug discovery for Alzheimer's disease and related tauopathies: a focus on tau assembly inhibitors.

  2010cited by this paper
• Sodium selenate specifically activates PP2A phosphatase, dephosphorylates tau and reverses memory deficits in an Alzheimer's disease model.

  2010cited by this paper
• Protective effects of xanthoceraside on learning and memory impairment induced by intracerebroventricular injections of Aβ_(1-42) in mice

  2010cited by this paper
• P2‐534: Efficacy of a novel, orally active GSK‐3 Inhibitor 6‐Methyl‐N‐[3‐[[3‐(1‐methylethoxy)propyl]carbamoyl]‐1H‐pyrazol‐4‐yl]pyridine‐3‐carboxamide in tau transgenic mice

  2009cited by this paper
• A novel GSK-3beta inhibitor reduces Alzheimer's pathology and rescues neuronal loss in vivo.

  2009cited by this paper
• Epigallocatechin gallate (EGCG) suppresses beta-amyloid-induced neurotoxicity through inhibiting c-Abl/FE65 nuclear translocation and GSK3 beta activation.

  2009cited by this paper
• Protective effects of xanthoceraside on learning and memory impairment induced by Aβ25–35 in mice

  2009influential reference
• Neuroprotective effects of donepezil through inhibition of GSK‐3 activity in amyloid‐β‐induced neuronal cell death

  2009cited by this paper
• A study of brain insulin receptors, AChE activity and oxidative stress in rat model of ICV STZ induced dementia.

  2009cited by this paper
• Mechanisms of tau-induced neurodegeneration

  2009cited by this paper
• Methylmercury induces neuropathological changes with tau hyperphosphorylation mainly through the activation of the c-jun-N-terminal kinase pathway in the cerebral cortex, but not in the hippocampus of the mouse brain.

  2009cited by this paper
• Tau phosphorylation: the therapeutic challenge for neurodegenerative disease.

  2009cited by this paper
• Dysregulation of insulin signaling, glucose transporters, O-GlcNAcylation, and phosphorylation of tau and neurofilaments in the brain: Implication for Alzheimer's disease.

  2009cited by this paper
• Biochemistry of Tau in Alzheimer’s disease and related neurological disorders

  2008cited by this paper
• Phosphatidylinositol-3-kinase activation blocks amyloid beta-induced neurotoxicity.

  2008cited by this paper
• Kainate induces AKT, ERK and cdk5/GSK3beta pathway deregulation, phosphorylates tau protein in mouse hippocampus.

  2007cited by this paper
• Insulin Dysfunction Induces In Vivo Tau Hyperphosphorylation through Distinct Mechanisms

  2007cited by this paper
• Improvement of ethanol extract from husk of Xanthoceras sorbifolia on rats with learning and memory dysfunction

  2007cited by this paper
• Tau phosphorylation and aggregation in Alzheimer's disease pathology

  2006cited by this paper
• Glycogen synthase kinase 3beta phosphorylates Alzheimer's disease-specific Ser396 of microtubule-associated protein tau by a sequential mechanism.

  2006cited by this paper
• Alzheimer‐like changes in protein kinase B and glycogen synthase kinase‐3 in rat frontal cortex and hippocampus after damage to the insulin signalling pathway

  2006cited by this paper
• Activation of glycogen synthase kinase-3 induces Alzheimer-like tau hyperphosphorylation in rat hippocampus slices in culture

  2005cited by this paper
• Contributions of protein phosphatases PP1, PP2A, PP2B and PP5 to the regulation of tau phosphorylation

  2005cited by this paper
• PS1 activates PI3K thus inhibiting GSK‐3 activity and tau overphosphorylation: effects of FAD mutations

  2004cited by this paper
• Akt activity in Alzheimer's disease and other neurodegenerative disorders

  2004cited by this paper
• AR-A014418, a selective GSK-3 inhibitor, produces antidepressant-like effects in the forced swim test.

  2004cited by this paper
• Plasma glycine and serine levels in schizophrenia compared to normal controls and major depression: relation to negative symptoms.

  2004cited by this paper
• Tau phosphorylation in neuronal cell function and dysfunction

  2004cited by this paper
• Glycogen synthase kinase-3 beta-mediated tau phosphorylation in cultured cell lines.

  2003cited by this paper
• Glycogen synthase kinase-3β-mediated tau phosphorylation in cultured cell lines

  2003cited by this paper
• The phosphoinositide 3-kinase pathway.

  2002cited by this paper
• Advances in Research on Xanthoceras sorbifolia

  2002cited by this paper
• Hormone replacement therapy and incidence of Alzheimer disease in older women: the Cache County Study.

  2002cited by this paper
• Selective small‐molecule inhibitors of glycogen synthase kinase‐3 activity protect primary neurones from death

  2001cited by this paper
• Decreased nuclear β‐catenin, tau hyperphosphorylation and neurodegeneration in GSK‐3β conditional transgenic mice

  2001cited by this paper
• Intracerebroventricular injection of streptozotocin in rats produces both oxidative stress in the brain and cognitive impairment.

  2001influential reference
• Delayed induction of αB‐crystallin in activated glia cells of hippocampus in kainic acid‐treated mouse brain

  2001cited by this paper
• Decreased nuclear beta-catenin, tau hyperphosphorylation and neurodegeneration in GSK-3beta conditional transgenic mice.

  2001cited by this paper
• Role of glycogen synthase kinase-3beta in neuronal apoptosis induced by trophic withdrawal.

  2000cited by this paper
• Tau protein isoforms, phosphorylation and role in neurodegenerative disorders.

  2000cited by this paper
• Distribution of Active Glycogen Synthase Kinase 3β (GSK-3β) in Brains Staged for Alzheimer Disease Neurofibrillary Changes

  1999cited by this paper
• Distribution of active glycogen synthase kinase 3beta (GSK-3beta) in brains staged for Alzheimer disease neurofibrillary changes.

  1999cited by this paper
• Intracerebroventricular administration of streptozotocin causes long-term diminutions in learning and memory abilities and in cerebral energy metabolism in adult rats.

  1998influential reference
• Accumulation of cyclin-dependent kinase 5 (cdk5) in neurons with early stages of Alzheimer's disease neurofibrillary degeneration.

  1998cited by this paper
• Lithium inhibits Alzheimer's disease‐like tau protein phosphorylation in neurons

  1997cited by this paper
• Lithium Reduces Tau Phosphorylation by Inhibition of Glycogen Synthase Kinase-3*

  1997cited by this paper
• Characterization of mAb AP422, a novel phosphorylation‐dependent monoclonal antibody against tau protein

  1996cited by this paper
• Proline-directed and Non-proline-directed Phosphorylation of PHF-tau (*)

  1995cited by this paper
• Phosphatase Activity Toward Abnormally Phosphorylated τ: Decrease in Alzheimer Disease Brain

  1995cited by this paper
• Phosphoprotein Phosphatase Activities in Alzheimer Disease Brain

  1993cited by this paper
• Phosphorylation affects the ability of tau protein to promote microtubule assembly.

  1984cited by this paper
• Psychopharmacology

  1979cited by this paper

• Bridging pathway dysfunction and therapy: novel compounds for neuroprotection

  2026cites this paper
• Treadmill Exercise Modulates the Leptin/LepR/GSK-3β Signalling Pathway to Improve Leptin Sensitivity and Alleviate Neuroinflammation in High-Fat Diet-Fed APP/PS1 Mice

  2025cites this paper
• β-pinene ameliorates ICV-STZ induced Alzheimer's pathology via antioxidant, anticholinesterase, and mitochondrial protective effects: In-silico and in-vivo studies.

  2025cites this paper
• Pseudoginsenoside-F11 reduces cognitive impairment and white matter injury in vascular dementia by alleviating autophagy-lysosomal pathway deficiency.

  2024cites this paper
• Eplingiella fruticosa leaf essential oil complexed with β-cyclodextrin exerts a neuroprotective effect in an Alzheimer’s disease animal model induced by Streptozotocin

  2024cites this paper
• Insights on therapeutic approaches of natural anti-Alzheimer's agents in the management of Alzheimer's disease: A future perspective

  2024cites this paper
• Discrepancy of synaptic and microtubular protein phosphorylation in the hippocampus of APP/PS1 and MAPT×P301S transgenic mice at the early stage of Alzheimer’s disease

  2023cites this paper
• Models of neuroinflammation for the assessment of kappa-opioid receptor ligands

  2023cites this paper
• Enhancement of oligodendrocyte autophagy alleviates white matter injury and cognitive impairment induced by chronic cerebral hypoperfusion in rats

  2023cites this paper
• Monitoring Alzheimer’s disease via ultraweak photon emission

  2023cites this paper
• The citrus flavonoid “Nobiletin” impedes STZ-induced Alzheimer’s disease in a mouse model through regulating autophagy mastered by SIRT1/FoxO3a mechanism

  2023cites this paper
• Therapeutic approaches using natural substances on the streptozotocin-induced animal model of sporadic Alzheimer’s disease: a systematic review

  2023influential citation
• Protective effect of 3-n-butylphthalide against intrastriatal injection of malonic acid-induced neurotoxicity and biochemical alteration in rats.

  2022cites this paper
• PINK1 regulates mitochondrial fission/fusion and neuroinflammation in β-amyloid-induced Alzheimer's disease models.

  2022cites this paper
• 7,8-Dihydroxyflavone improves cognitive functions in ICV-STZ rat model of sporadic Alzheimer’s disease by reversing oxidative stress, mitochondrial dysfunction, and insulin resistance

  2021cites this paper
• Mangostanaxanthone IV Ameliorates Streptozotocin-Induced Neuro-Inflammation, Amyloid Deposition, and Tau Hyperphosphorylation via Modulating PI3K/Akt/GSK-3β Pathway

  2021cites this paper
• Tau Cleavage Contributes to Cognitive Dysfunction in Strepto-Zotocin-Induced Sporadic Alzheimer’s Disease (sAD) Mouse Model

  2021cites this paper
• The Tragedy of Alzheimer’s Disease: Towards Better Management via Resveratrol-Loaded Oral Bilosomes

  2021cites this paper
• Combination of docosahexaenoic acid and Ginko biloba extract improves cognitive function and hippocampal tissue damages in a mouse model of Alzheimer's disease.

  2021cites this paper
• Xanthoceraside administration produces significant antidepressant effects in mice through activation of the hippocampal BDNF signaling pathway.

  2021cites this paper
• Protective Effect of Biobran/MGN-3 against Sporadic Alzheimer's Disease Mouse Model: Possible Role of Oxidative Stress and Apoptotic Pathways

  2021cites this paper
• SCR-1693 inhibits tau phosphorylation and improves insulin resistance associated cognitive deficits.

  2020cites this paper
• Transforming growth factor β1 restores hippocampal synaptic plasticity and memory loss in an Alzheimer’s disease model through the PI3K/Akt signaling pathway

  2020cites this paper
• Moderate protective effect of Kyotorphin against the late consequences of intracerebroventricular streptozotocin model of Alzheimer’s disease

  2019cites this paper
• Xanthoceraside prevented synaptic loss and reversed learning-memory deficits in APP/PS1 transgenic mice

  2019cites this paper
• Natural barrigenol-like triterpenoids: A comprehensive review of their contributions to medicinal chemistry.

  2019cites this paper
• Neuroprotective Approach of Anti-Cancer Microtubule Stabilizers Against Tauopathy Associated Dementia: Current Status of Clinical and Preclinical Findings

  2019cites this paper
• Current anti-Alzheimer's disease effect of natural products and their principal targets.

  2019cites this paper
• Interaction between hyperphosphorylated tau and pyroptosis in forskolin and streptozotocin induced AD models.

  2019cites this paper
• Hypercapnic and Hypoxic Respiratory Response During Wakefulness and Sleep in a Streptozotocin Model of Alzheimer’s Disease in Rats

  2018cites this paper
• Targeting central &bgr;2 receptors ameliorates streptozotocin‐induced neuroinflammation via inhibition of glycogen synthase kinase3 pathway in mice

  2018cites this paper
• Determination and Pharmacokinetics of WGA in Rat Plasma by LC-MS After Oral Administration of Xanthoceras sorbifolia Bunge Extract.

  2018cites this paper
• 5-HT6 receptor agonist and antagonist modulates ICV-STZ-induced memory impairment in rats

  2018cites this paper
• Protein phosphatase 2A and tau: an orchestrated ‘Pas de Deux’

  2018cites this paper
• Recent Trends in Drug Discovery against Alzheimer's Disease: Use of Natural Products and Nutraceuticals from Botanicals

  2018cites this paper
• Human chorionic gonadotropin decreases the phosphorylated tau protein level in streptozotocin-Alzheimeric male rats' hippocampus.

  2018cites this paper
• Nicotinamide loaded functionalized solid lipid nanoparticles improves cognition in Alzheimer’s disease animal model by reducing Tau hyperphosphorylation

  2018cites this paper
• Protective effect of valproic acid in streptozotocin-induced sporadic Alzheimer’s disease mouse model: possible involvement of the cholinergic system

  2017cites this paper
• Comparative Behavioural Study of Unilateral and Bilateral Intrahippocampal Injection of Streptozotocin for Alzheimer’s Disease Rat Model

  2017cites this paper
• A study on the effect of ion chelating agent on Alzheimer disease

  2017cites this paper
• Natural products against Alzheimer's disease: Pharmaco-therapeutics and biotechnological interventions.

  2017influential citation
• The total triterpenoid saponins of Xanthoceras sorbifolia improve learning and memory impairments through against oxidative stress and synaptic damage.

  2017cites this paper
• Adiponectin Attenuates Streptozotocin-Induced Tau Hyperphosphorylation and Cognitive Deficits by Rescuing PI3K/Akt/GSK-3β Pathway

  2017cites this paper
• Arctigenin Attenuates Learning and Memory Deficits through PI3k/Akt/GSK-3β Pathway Reducing Tau Hyperphosphorylation in Aβ-Induced AD Mice

  2016cites this paper
• Xanthoceraside hollow gold nanoparticles, green pharmaceutics preparation for poorly water-soluble natural anti-AD medicine.

  2016cites this paper
• Intracerebroventricular Streptozotocin as a Model of Alzheimer’s Disease: Neurochemical and Behavioral Characterization in Mice

  2016cites this paper
• Rodent models of neuroinflammation for

  2015cites this paper
• Rodent models of neuroinflammation for Alzheimer’s disease

  2015cites this paper
• Minocycline protects against lipopolysaccharide-induced cognitive impairment in mice

  2015cites this paper
• Multi-target iron-chelators improve memory loss in a rat model of sporadic Alzheimer's disease.

  2015cites this paper
• Magnesium Protects Cognitive Functions and Synaptic Plasticity in Streptozotocin-Induced Sporadic Alzheimer’s Model

  2014cites this paper
• Pterostilbene attenuates lipopolysaccharide-induced learning and memory impairment possibly via inhibiting microglia activation and protecting neuronal injury in mice.

  2014cites this paper
• Cognitive Enhancers (Nootropics). Part 3: Drugs Interacting with Targets other than Receptors or Enzymes. Disease-Modifying Drugs. Update 2014

  2014cites this paper
• Effects of Treadmill Exercise on Brain Insulin Signaling, Glucose Metabolism and Tau Hyperphosphorylation in Intracerebroventricular Streptozotocin Induced-Memory Impairment in Rats

  2014cites this paper
• Cognitive Enhancers (Nootropics). Part 3: Drugs Interacting with Targets other than Receptors or Enzymes. Disease-modifying Drugs

  2013cites this paper